Clinical trial · Interventional
Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma
Treatment for Newly Diagnosed Patients With Stage III/IV Non-Hodgkin Lymphoma-Study XIII (A Therapeutic Pilot Study)
NCT00187122CI-TRIAL-00001422completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this study is to determine if it is feasible to administer an intensified, multi-agent chemotherapy regimen for children with stage III and IV non-Hodgkin lymphoma and to find out what the toxicities are.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoblastic Lymphoma | Lymphoblastic Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (11)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Cytarabine | Drug | Cytarabine | ALIAS |
| Daunomycin | Drug | Daunorubicin | ALIAS |
| Dexamethasone | Drug | Dexamethasone | ALIAS |
| Etoposide | Drug | Etoposide | ALIAS |
| L-Asparaginase | Drug | Asparaginase | ALIAS |
| Mercaptopurine | Drug | Mercaptopurine | ALIAS |
| Methotrexate | Drug | Methotrexate | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- 1
- description
- See Detailed Description section for description of treatment plan.
- interventionNames
- Drug: Vincristine
- Procedure: Radiation Therapy
- Drug: Daunomycin
- Drug: L-Asparaginase
- Drug: Cytarabine
- Drug: Methotrexate
- Drug: Mercaptopurine
- Drug: Etoposide
- Drug: Cyclophosphamide
- Drug: Prednisone
- Drug: Dexamethasone
Primary outcomes (1)
- measure
- To determine toxicity and feasibility of intensified multiagent chemotherapy and high dose methotrexate.
- timeFrame
- Within first 30 days following pre-induction chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Stage III or IV Lymphoblastic Lymphoma * One week or less of prior therapy, only to include steroids, vinca alkaloids, and emergency radiation therapy to the mediastinum in those with severe respiratory. Exclusion criteria: * Patients with superior vena cava syndrome, significant compression of the trachea requiring more than 40% oxygen or having significant dyspnea at normal activity
References
Publications (0)
Data not yet available
No reference posted for this study.